
Don't Skip A Travel Insurance Agent — Here's Why
After a horrifying ski accident, the author learned a lesson about the importance of a good insurance agent.
I discovered the importance of having a good travel insurance agent on an icy slope in the Swiss Alps. My painful accident happened in a split second, but it took more than two years for me to learn my lesson.
I'm an experienced skier, but I seriously misjudged my first run of the season at Arosa, a resort in the picturesque Graubünden region. I slipped on a patch of ice buried under a dusting of fresh snow, faceplanted, and couldn't get up.
The next 48 hours were a blur. I remember a helicopter, and a doctor jumping out and asking me if I could still feel my legs. Lots of painkillers. And a horrifying diagnosis: A broken pelvis and three broken ribs.
At the end of my stay in the hospital, a young man from the accounting department appeared at my bedside and asked for my insurance information. I also remember calling GeoBlue, my travel medical insurance provider, to let them know where I was and that the hospital would be contacting them soon.
I was on crutches for a few weeks, and I hobbled around for the next five months. Paracetamol was my best friend. I focused on getting better and assumed that between the guy from accounting and my call to GeoBlue, everything was settled.
It was not.
More than two years later, the hospital sent me a bill for $14,543. GeoBlue refused to pay the claim because it said that I waited too long.
"Travel insurance isn't a small decision for a big trip," says James Nuttall, vice president of operations at Insubuy. "It makes sense to consult with an expert."
Whether you're working with an insurance agent for travel medical insurance or a travel advisor for trip insurance, an expert can guide you in several key ways:
Pro tip: If you're doing something exotic — like technical diving, mountain climbing, or um, skiing — an agent is a must, says Mark Whitman, an insurance specialist with Rise & Shield. "If your trip includes altitude, reefs, or any other potential curveballs, talk to an expert," he advises. "Get a policy designed for your idea of fun — before you end up facing a claim no one saw coming."
Of course, you can buy travel insurance directly, and you might end up with a great policy. But purchasing one through an expert — either a travel agent or an insurance agent — adds an important benefit.
"While it's possible to buy travel insurance on your own, a travel advisor can help you find the best product for your specific itinerary and feel confident that your travel investment is protected," says Robert Gallagher, president of the US Travel Insurance Association. "When it comes time to file a claim, they can also help tremendously with documentation."
It's important to distinguish between insurance agents and travel agents, notes Louise Norris, a health policy analyst for healthinsurance.org. "Insurance agents are licensed by the insurance department of any state in which they sell coverage," she says. "Travel agents are subject to different registration requirements that vary by state." She says some travel agents offer travel insurance as part of the packages they provide, but they may not be as well-versed in the nuances of the insurance coverage provisions as a licensed insurance agent would be.
But the bottom line, according to experts, is that having any agent can really help.
"Buying travel insurance through an agent ensures travelers don't miss critical details, like understanding medical exclusions or knowing which parts of their trip costs should be covered," says Nicole Perreault, chief operating officer of AXA Partners US.
I asked Stephanie Goldberg-Glazer, a travel advisor with Live Well, Travel Often, to run through the list of things she does for her clients if they have to file a claim.
"We walk them through the entire claims process, beginning to end," she explains. "So, when the claim is initially filed, we gather all of the paperwork, and help them navigate through exactly what is required by the claim analysts."
But it doesn't end there. While most travel insurance claims are paid quickly, some drag on. That's where the Live Well, Travel Often team comes in.
"We follow up with the analysts throughout the process, until the claim is resolved," she says.
Note: Some travel advisors don't offer this service, so it's worth asking before you hire a travel advisor. If they say "yes," it may be worth giving them your business.
Rachel Wagner used an agent to buy her travel insurance policy for a recent transatlantic cruise. Her husband contracted COVID and pneumonia and spent three days in the ship's medical center and another two weeks in the hospital.
Her adviser held her hand through the entire experience, explaining the claims process and guiding her through the steps.
"Ours was a complicated claim and I'm so thankful that we didn't have to wade through this daunting process alone," says Wagner, a consultant from Bixby, Okla.
Lucky her. But could an agent rescue me from a $14,543 bill?
I wasn't surprised by GeoBlue's denial of my claim. Most major insurance companies give you 12 months from the date of service to file your paperwork. But these were special circumstances. It turns out the hospital had obtained a guarantee of payment from GeoBlue, but instead of following through, it decided to bill me two years later.
Worse, the hospital had sent me a bill that claimed this was their second notice and had already applied some late fees. But it was the first notice I had received. After getting a rejection from GeoBlue, I called the company to inquire about an appeal. A representative walked me through the steps in a phone call but didn't give me much hope. Too much time had elapsed.
Still, I filed an appeal, in which I carefully explained what happened. I hoped GeoBlue would grant an exception to its 12-month limit on filing claims. I honestly believed that the hospital was working directly with my insurance company. Looking back, that was a mistake. I should have called the insurance company after my discharge to ensure that they were actively working on my claim. Nothing is automatic.
A few weeks later, I got a random email from my insurance agent, Joe Cronin at International Citizens Insurance, asking how I was doing. Cronin hadn't sold me the GeoBlue policy, but he helped me find my current travel medical policy. I mentioned that I was having trouble with a medical claim.
Two weeks later, a senior claims adjuster at GeoBlue called me. They had heard from Cronin, found my appeal, listened to the phone calls and reviewed the paperwork — and decided to pay the claim in full.
It's unclear if GeoBlue would have eventually considered my appeal, but I know that Cronin's advocacy on my behalf gave the insurance company a little nudge.
"An agent is there to advocate for you in emergencies and to navigate some of the more complicated processes involved in a claim," Cronin explained. "This is a big part of our value."
I'm forever grateful for that. And I'm also grateful that GeoBlue decided to honor my claim.
"In an industry where fine print can make or break a trip, having a knowledgeable travel insurance agent is essential," says Ned Tadic, a spokesman for Squaremouth. "A knowledgeable agent can help provide clarity, ensure travelers are truly protected, and serve as an advocate when unexpected events disrupt plans — and we've been seeing a lot of disruptions happen as of late."
So my lesson, two years in the making, is this: Choose your insurance agent as carefully as you would your policy. Good agents won't just help you select the right policy for you. They'll also ensure your claim gets the attention it deserves.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
13 hours ago
- CBS News
Major delay on BART Richmond line because of "major medical emergency" at North Berkeley station
What was described as a "major medical emergency" at the North Berkeley BART station led to major delays on the Richmond line Monday morning, the agency said. Just after 10 a.m., BART said the North Berkeley station was closed because of the incident, which halted Red Line service and led to delays on the line in all directions. A BART spokesperson said preliminary information was that a person entered the trackway, and a collision may have occurred with a train. Later, spokesperson Chris Filippi said that a person was removed from the trackway and was taken to a hospital. The station was reopened just before 11 a.m. and Red Line service resumed, but residual delays remained.
Yahoo
a day ago
- Yahoo
Amicomed by Newel Health obtains EU MDR certification as a digital medical device for hypertension management
BASEL, Switzerland and MILAN, June 9, 2025 /PRNewswire/ -- Newel Health, a European HealthTech company specialized in certified digital medical devices, announced today that Amicomed, its solution for hypertension management, has received CE certification as a Class IIa medical device under the European Medical Device Regulation (MDR 2017/745). This milestone positions Amicomed among the leading candidate digital therapies poised to reshape hypertension management in Europe. Amicomed supports individuals in daily blood pressure self-management by offering personalized feedback based on real-world data and helping users between clinical visits. It captures structured blood pressure data and translates it into clinically meaningful insights for users and healthcare professionals. Key features include medication reminders to improve adherence and personalized lifestyle and dietary recommendations based on the user's clinical profile. In addition to its direct-to-consumer application, Amicomed can be deployed as a digital companion to antihypertensive therapies. It supports medication adherence and generates longitudinal behavioral insights. The solution has also been validated in population health programs for cardiovascular risk monitoring and chronic care optimization, as well as in digital insurance models focused on prevention and risk management. These use cases create pathways for adoption across pharmaceutical, insurance, and institutional ecosystems. "We designed Amicomed to offer a digital therapy that fits into people's everyday lives, supporting them, day by day, in managing hypertension," said Ervin Ukaj, CEO of Newel Health. "The MDR certification confirms the strength of our platform and the reliability of our regulatory approach, enabling us to bring Amicomed to millions of individuals across Europe and to pursue scalable growth in partnership with public and private healthcare stakeholders." Certified. Scalable. Integration-ready. Compatible with Apple Health, Google Fit, and major Bluetooth-enabled blood pressure monitors, Amicomed also accepts manual data entry, ensuring usability without connected devices. It provides users with weekly reports, personalized notifications, and structured summaries, while clinicians can monitor progress between visits. "Amicomed transformed available cardiovascular knowledge into a robust, intuitive digital solution designed for large-scale adoption," commented Professor Domenico Cianflone, member of the Scientific Advisory Board of Newel Health. Amicomed will be distributed through a multi-channel strategy that includes direct-to-consumer, health insurance partners, digital pharmacies, corporate wellness programs, and public healthcare systems. Strategic discussions and pilot programs are currently underway across several European countries. Powered by AI and personalization at the center Amicomed is built on Newel Health's proprietary platform that integrates clinical logic, behavioral science, and real-world data to deliver personalized digital therapeutic pathways. uses predictive models powered by artificial intelligence to improve behavioral segmentation, sustain engagement, and adapt interventions to the individual profile. The platform ensures clinical consistency, scalability, and alignment with international standards for safety, performance, and software quality. About Newel Health Newel Health is a European HealthTech company developing certified digital medical devices that combine clinical science, behavioral psychology, and intelligent technology. With teams in Milan, Basel, Salerno and Tallinn, the company creates software-based therapeutics that address chronic diseases where user behavior and real-world data are central to clinical outcomes. At Newel, user experience is part of the clinical model. Every solution is designed to be intuitive, engaging, and scalable. Through its proprietary platform Newel enables continuous product optimization informed by behavioral analytics and longitudinal health signals. Newel operates a full-stack infrastructure for the development, certification, and commercialization of software as a medical device across global markets, including the European Union, the United States, and China. The company works with pharmaceutical leaders, health insurers, and public health systems to co-develop and scale regulated therapeutics that are clinically validated, commercially viable, and globally deployable. Newel's portfolio includes certified therapeutics for hypertension (Amicomed) and chronic pain (Rohkea), with additional programs in Parkinson's disease, metabolic health, and cardiovascular prevention advancing through development. For more information: contact: media@ Photo - - View original content to download multimedia: Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
a day ago
- Yahoo
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs. Some of these preclinical data with Addex GABAB PAM drug candidate will be presented on June 7, 2025 at the 10th American Cough Conference, in Dulles, Virginia by Dr Mikhail Kalinichev, Head of Translational Science at Addex. In models of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the Addex GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the tolerability of the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound's activity on respiratory rate. 'The preclinical data obtained to date demonstrate the huge therapeutic potential of our highly selective GABAB PAM. Following in vivo proof of concept seen in a range of cough models, we are now ready to advance this candidate molecule into IND enabling studies,' said Dr Kalinichev. 'Chronic cough continues to be difficult to treat, and several different approaches being evaluated in clinical trials. Based on the data we have collected to date, we believe our GABAB PAM candidate has the potential to be an effective, once-daily treatment for patients with refractory chronic cough and other conditions.' 'This data with our novel, once daily, orally available GABAB PAM drug candidate clearly demonstrates the potential of our allosteric modulator approach to deliver a better effect than baclofen for this clinically validated drug target,' said Tim Dyer, CEO of Addex. 'Congratulations to the team and we look forward to advancing this candidate rapidly through IND enabling studies and into the clinic so we can hopefully provide better treatment options for patients.' About GABAB activation and cough: The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed on airways and in the central and peripheral components of the cough neural circuit. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound. About Addex Therapeutics:Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55 PR@ Mike SinclairPartner, Halsin Partners+44 (0)7968 022075msinclair@ Addex Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data